{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    9,
    10,
    12,
    14,
    18,
    20,
    22,
    25,
    26,
    151
  ],
  "modelUsed": "claude-opus-4-5",
  "advanced": {
    "studyAmendments": [
      {
        "id": "amend_1",
        "number": "1",
        "scope": {
          "code": "Global",
          "codeSystem": "USDM",
          "decode": "Global"
        },
        "instanceType": "StudyAmendment",
        "summary": "No summary available in the provided document.",
        "effectiveDate": "2022-12-15",
        "reasonIds": [
          "ar_1_1"
        ],
        "previousVersion": "Original Protocol",
        "newVersion": "Amendment 1"
      },
      {
        "id": "amend_2",
        "number": "2",
        "scope": {
          "code": "Global",
          "codeSystem": "USDM",
          "decode": "Global"
        },
        "instanceType": "StudyAmendment",
        "summary": "The overall reasons for this protocol amendment are to: Revise inclusion and exclusion criteria to improve feasibility of study conduct at a variety of clinical sites. Clarify contraception methods for male study participants and for female sexual partners of male participants. Add an additional part to the baseline visit to allow confirmation of eligibility on the basis of liver chemistry tests before dosing. Clarify acceptable conditions for repeating screening laboratory samples. Allow flexibility to perform Week -6 and Week 24 assessments on different days within the specified visit window.",
        "effectiveDate": "2023-04-25",
        "reasonIds": [
          "ar_2_1",
          "ar_2_2"
        ],
        "previousVersion": "Amendment 1",
        "newVersion": "Amendment 2"
      },
      {
        "id": "amend_3",
        "number": "3",
        "scope": {
          "code": "Global",
          "codeSystem": "USDM",
          "decode": "Global"
        },
        "instanceType": "StudyAmendment",
        "summary": "The overall reasons for this protocol amendment are to: Revise inclusion and exclusion criteria to improve study feasibility. Clarify the screening period eligibility and extension of its duration. Clarify the acceptable conditions for including severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-infected participants into the study and to allow adequate time for recovery of symptoms before screening.",
        "effectiveDate": "2023-09-18",
        "reasonIds": [
          "ar_3_1",
          "ar_3_2"
        ],
        "previousVersion": "Amendment 2",
        "newVersion": "Amendment 3"
      }
    ],
    "amendmentReasons": [
      {
        "id": "ar_1_1",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_1",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_2",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_3_1",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_3_2",
        "code": "REGULATORY",
        "description": "Regulatory",
        "instanceType": "AmendmentReason"
      }
    ],
    "countries": [
      {
        "id": "country_1",
        "name": "United States",
        "instanceType": "Country",
        "code": "US"
      }
    ],
    "studySites": [],
    "summary": {
      "amendmentCount": 3,
      "countryCount": 1,
      "siteCount": 0
    },
    "geographicScope": {
      "id": "geo_1",
      "name": "Study Geographic Scope",
      "scopeType": "National",
      "instanceType": "GeographicScope",
      "countryIds": [
        "country_1"
      ],
      "regions": [
        "North America"
      ]
    }
  },
  "rawResponse": {
    "amendments": [
      {
        "number": "1",
        "effectiveDate": "2022-12-15",
        "summary": "No summary available in the provided document.",
        "previousVersion": "Original Protocol",
        "newVersion": "Amendment 1",
        "reasons": [
          "Administrative"
        ]
      },
      {
        "number": "2",
        "effectiveDate": "2023-04-25",
        "summary": "The overall reasons for this protocol amendment are to: Revise inclusion and exclusion criteria to improve feasibility of study conduct at a variety of clinical sites. Clarify contraception methods for male study participants and for female sexual partners of male participants. Add an additional part to the baseline visit to allow confirmation of eligibility on the basis of liver chemistry tests before dosing. Clarify acceptable conditions for repeating screening laboratory samples. Allow flexibility to perform Week -6 and Week 24 assessments on different days within the specified visit window.",
        "previousVersion": "Amendment 1",
        "newVersion": "Amendment 2",
        "reasons": [
          "Operational",
          "Administrative"
        ]
      },
      {
        "number": "3",
        "effectiveDate": "2023-09-18",
        "summary": "The overall reasons for this protocol amendment are to: Revise inclusion and exclusion criteria to improve study feasibility. Clarify the screening period eligibility and extension of its duration. Clarify the acceptable conditions for including severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)-infected participants into the study and to allow adequate time for recovery of symptoms before screening.",
        "previousVersion": "Amendment 2",
        "newVersion": "Amendment 3",
        "reasons": [
          "Operational",
          "Regulatory"
        ]
      }
    ],
    "geographicScope": {
      "type": "National",
      "countries": [
        {
          "name": "United States",
          "code": "US"
        }
      ],
      "regions": [
        "North America"
      ],
      "plannedSites": 20
    },
    "sites": []
  }
}